J
Joseph R. Taylor
Researcher at Bristol-Myers Squibb
Publications - 11
Citations - 1111
Joseph R. Taylor is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: 11β-hydroxysteroid dehydrogenase type 1 & In vivo. The author has an hindex of 7, co-authored 10 publications receiving 1003 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Wei Meng,Bruce A. Ellsworth,Alexandra A. Nirschl,P.J. McCann,Manorama Patel,Ravindar N. Girotra,Gang Wu,Philip M. Sher,Eamonn P. Morrison,Scott A. Biller,Robert Zahler,Prashant P. Deshpande,Annie Pullockaran,Deborah Hagan,Nathan Morgan,Joseph R. Taylor,Mary T. Obermeier,William G. Humphreys,Ashish Khanna,Lorell Discenza,James G. Robertson,Aiying Wang,Songping Han,John R. Wetterau,Evan B. Janovitz,Oliver P. Flint,Jean M. Whaley,William N. Washburn +27 more
TL;DR: The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats.
Journal ArticleDOI
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Songping Han,Deborah Hagan,Joseph R. Taylor,Li Xin,Wei Meng,Scott A. Biller,John R. Wetterau,William N. Washburn,Jean M. Whaley +8 more
TL;DR: In vivo and in vitro data suggest that dapagliflozin has the potential to be an efficacious treatment for type 2 diabetes.
Journal ArticleDOI
Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity
Claudio Mapelli,Sesha Natarajan,Jean-Philippe Meyer,Bastos Margarita M,Michael S. Bernatowicz,Ving G. Lee,Jelka Pluscec,Douglas James Riexinger,Ellen Sieber-McMaster,Keith L. Constantine,Constance Smith-Monroy,Rajasree Golla,Zhengping Ma,Daniel Longhi,Dan Shi,Li Xin,Joseph R. Taylor,Barry Koplowitz,Cecilia L Chi,Ashish Khanna,Gordon William Robinson,Ramakrishna Seethala,Ildiko Antal-Zimanyi,Robert H. Stoffel,Songping Han,Jean M. Whaley,Christine Huang,John Krupinski,William R. Ewing +28 more
TL;DR: The discovery of a novel class of 11 amino acid GLP-1 receptor agonists, which consist of a structurally optimized 9-mer, which is closely related to the N-terminal 9 amino acids ofglucagon-like peptide 1, linked to a substituted C-Terminal biphenylalanine (BIP) dipeptide.
Journal ArticleDOI
11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice.
Ricardo Garcia,Debra Search,John A. Lupisella,Jacek Ostrowski,Bo Guan,Jian Chen,Wen-Pin Yang,Amy Truong,Aiqing He,Rongan Zhang,Mujing Yan,Samuel Hellings,Peter S. Gargalovic,Carol S. Ryan,Linda Watson,Robert Langish,Petia Shipkova,Nancy L. Carson,Joseph R. Taylor,Richard Yang,George C. Psaltis,Thomas Harrity,Jeffrey A. Robl,David A. Gordon +23 more
TL;DR: Findings suggest that 11βHSD1 inhibition may have the potential to limit plaque development at the vessel wall and regulate foam cell formation independent of changes in plasma lipids.
Journal ArticleDOI
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).
Shung C. Wu,David S. Yoon,Janice Chin,Katy Van Kirk,Ramakrishna Seethala,Rajasree Golla,Bin He,Thomas Harrity,Lori Kunselman,Nathan Morgan,Randolph P. Ponticiello,Joseph R. Taylor,Rachel Zebo,Timothy W. Harper,Wenying Li,Mengmeng Wang,Lisa Zhang,Bogdan Sleczka,Akbar Nayeem,Steven Sheriff,Daniel M. Camac,Paul E. Morin,John G. Everlof,Yi-Xin Li,Cheryl Ferraro,Kasia Kieltyka,Wilson Z. Shou,Marianne Vath,Tatyana Zvyaga,David A. Gordon,Jeffrey A. Robl +30 more
TL;DR: Optimization of substituents at the 1 and 4 positions of the isoquinoline group in addition to the core modifications, with a special focus on enhancing metabolic stability and aqueous solubility, resulted in the identification of several compounds as potent advanced leads.